umbilical cord stem cells
Recently Published Documents


TOTAL DOCUMENTS

85
(FIVE YEARS 28)

H-INDEX

15
(FIVE YEARS 2)

2021 ◽  
Author(s):  
Yantong Wang ◽  
Simin Zhang ◽  
Haoqing Yang ◽  
Yangyang Cao ◽  
Dianqin Yu ◽  
...  

Abstract Background: To investigate the effect of miR‐196a-5p on the osteogenic differentiation and defected bone repair of Wharton’s jelly umbilical cord stem cells (WJCMSCs). Methods: miR‐196a-5p mimic or inhibitor was applied to overexpress or silence miR‐196a-5p expression in WJCMSCs. The alkaline phosphatase (ALP) activity, mineralization ability, and osteogenic markers expression were used to test WJCMSCs osteogenic potential in vitro. Calvarial bone defect model of rat was used to evaluate WJCMSCs bone regeneration ability in vivo. mRNA microarray was used to reveal the underling mechanisms that miR‐196a-5p regulated bone repair.Results: miR-196a-5p inhibition reduced the ALP activity, mineralization ability, and level of osteogenic markers OCN, DSPP, DMP1 and BSP, while miR-196a-5p overexpression enhanced the ALP activity, mineralization ability, and level of OCN, DSPP, DMP1 and BSP of WJCMSCs in vitro. Next, the micro-CT and histopathology results showed miR-196a-5p-overexpressed-WJCMSCs obviously promoted the new bone tissue regeneration and calvarial bone defect repair after MSCs transplanted for 12 weeks. Further, mRNA microarray of miR-196a-5p-overexpressed-WJCMSCs revealed totally 959 significantly differentially expressed genes (DEGs), among which 34 upregulated and 925 downregulated. Also, 241 miR-196a-5p targeted genes were predicted by using miRNA targeted websites and only 19 predicted genes were consistent with microarray results. On this basis, one significantly downregulated gene SERPINB2 was selected and revealed that SERPINB2 deletion obviously enhanced the ALP activity and mineralization ability of WJCMSCs in vitro.Conclusions: miR-196a-5p promoted the osteogenic differentiation potential and calvarial bone defect repair ability of WJCMSCs. And SERPINB2 acted as one key downstream gene to participate in the miR-196a-5p promoted MSCs osteogenic differentiation.


Separations ◽  
2021 ◽  
Vol 8 (5) ◽  
pp. 61
Author(s):  
Chao-Hsing Kao

Concentrated growth factors are extracted from platelet-rich plasma obtained from healthy adult veins by physical gradient centrifugation, and the activated platelets release various growth factors and cytokines, which can be further converted into concentrated growth factors liquid or gel preparations by different centrifuge tubes. These preparations are widely used in clinical treatments in various fields, such as dentistry, dermatology and surgery. In this article, concentrated growth factors gel and platelet-poor plasma gel obtained from six healthy adults were pressed into a concentrated growth factors membrane and platelet-poor plasma membrane. We examined whether the 3D fibrin mesh and the various concentrated growth factors within the concentrated growth factors membrane could be used as a bioscaffold for the human Wharton’s jelly umbilical cord stem cell line or the HaCaT cell line to attach, proliferate and form epidermal-like tissue. We also aimed to implant umbilical cord stem cells on the concentrated growth factors membrane or platelet-poor plasma membrane, and further compare the characteristics of similar tissues after 4 weeks in in vitro culture. The results showed that human Wharton’s jelly umbilical cord mesenchymal stem cells, implanted on the upper surface of the concentrated growth factors membrane, showed subsequent cell attachment and proliferation. After 4 weeks of ex vivo tissue culture, a multi-layer epidermal-like tissue formed on the upper surface of the membrane containing concentrated growth factors. This tissue had a minimum thickness of 89.91 µm to a maximum of 204.19 µm, mean ± SD = 144.36 µm ± 43.14 µm. Sections of these multi-layer epidermal-like tissues were used for immunohistochemical staining. We found that 79.8% ± 7.2% of the cells expressed the pancytokeratin marker, 29.5% ± 9.4% of the cells expressed the P63 marker, and 71.7% ± 3.9% of the cells expressed the vimentin marker. After the same 4 weeks in the in vitro culture, the HaCaT cells could attach to the concentrated growth factors membrane and proliferate to form a multi-layer tissue, The tissue had a minimum thickness of 63.17 µm to a maximum of 100.26 µm, mean ± SD = 74.05 µm ± 13.44 µm. We found that 88.1% ± 4.9% of the cells expressed the pancytokeratin marker, 63.6% ± 11.4% of the cells expressed the P63 marker, and 79% ± 9.9% of the cells expressed the vimentin marker. Also, after 4 weeks in the in vitro culture, it showed that umbilical cord stem cells could attach to the platelet-poor plasma membrane, proliferate and distribute in the whole-tissue sections. We found that 9.7% ± 2.4% of the cells expressed the pancytokeratin marker, 7.45% ± 1.9% of the cells expressed the P63 maker, and 95.9% ± 3.7% of the cells expressed the vimentin marker. In terms of the percentage of umbilical cord stem cells expressing pancytokeratin, P63, or vimentin cell markers, there was a significant difference between cultivating in the concentrated growth factors membrane scaffold and the platelet-poor plasma membrane scaffolds. In terms of the percentage of umbilical cord stem cells or HaCaT cells (cultivating in the concentrated growth factors membrane) expressing pancytokeratin, P63, or vimentin cell markers, there was no significant difference. These results suggested that umbilical cord Wharton’s jelly mesenchymal stem cells can use the concentrated growth factors membrane (composed of 3D fibrin mesh, and various growth factors and cytokines) as an effective and self-contained bioscaffold to differentiate towards keratinocytes-like cells. In the future, donors’ own concentrated growth factors membrane can be applied as an auxiliary tool for autologous tissue regeneration.


2020 ◽  
Vol 6 (6) ◽  
pp. 1-8
Author(s):  
Dennis Smiler ◽  

Combining bone-marrow aspirate with xenograft and allograft particulate material has been demonstrated to produce a significant quantity of new bone growth. However, securing 1 to 4 ccs of adult autogenous stem cells by means of bone-marrow aspiration is invasive, and the aspirated stem cells are typically senescent, as the procedure most often is used in aging patients


FEBS Open Bio ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 278-288
Author(s):  
Xiao Han ◽  
Haoqing Yang ◽  
Huina Liu ◽  
Chen Zhang ◽  
Yangyang Cao ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Juehong Li ◽  
Zhixiao Yao ◽  
Hao Xiong ◽  
Haomin Cui ◽  
Xu Wang ◽  
...  

Abstract Background Peritendinous fibrosis represents a fibrotic healing process that usually occurs after tendon injury or surgery. This worldwide challenge hampers the functional rehabilitation and the mobility of extremities. However, effective treatment is still lacking at present. The aim of our study was to explore the effect of extracellular vesicles derived from hydroxycamptothecin primed human umbilical cord stem cells (HCPT-EVs) on post-traumatic tendon adhesion. Methods Extracellular vesicles derived from unprimed human umbilical cord mesenchymal stem cells (Unprimed EVs) or HCPT-EVs were isolated and characterized. A rat model of Achilles tendon injury was used to confirm the anti-adhesion effect of HCPT-EVs and compared with that of Unprimed EVs in vivo. In vitro, the inhibitory effects of HCPT-EVs on fibroblast proliferation, viability, and myofibroblast differentiation upon TGF-β1 stimulation were compared with the effects of Unprimed EVs. For mechanistic analysis, the expression of endoplasmic reticulum stress (ERS)-associated proteins was examined among the effector cargos of HCPT-EVs and Unprimed EVs. The ERS antagonist salubrinal was used to determine the ERS dependence of the anti-adhesion effects of HCPT-EVs. Results There were no obvious differences between Unprimed EVs and HCPT-EVs in terms of morphology, particle size, characteristic protein expression, and cellular uptake. HCPT-EVs exhibited a fortified anti-adhesion effect after Achilles tendon injury compared with Unprimed EVs. Fibroblast proliferation and viability and myofibroblast differentiation were all inhibited by HCPT-EVs. These properties were superior for HCPT-EVs relative to Unprimed EVs. Mechanistically, HCPT-EVs contained more ERS-associated protein than Unprimed EVs and activated the ERS pathway in fibroblast to counteract myofibroblast differentiation. Conclusion This study demonstrates that HCPT-EVs show high anti-adhesion potential for the treatment of tendon injury by provoking ERS in fibroblasts. HCPT-EVs represent a promising strategy for clinical use in treating adhesion-related diseases.


2020 ◽  
Vol 8 (2) ◽  
pp. 78-82
Author(s):  
Katarzyna Stefańska ◽  
Rut Bryl ◽  
Greg Hutchings ◽  
Jamil A. Shibli ◽  
Marta Dyszkiewicz-Konwińska

AbstractStem cells are now one of the most extensively studied fields in experimental medicine. Although embryonic stem cells (ESCs) have the capability to differentiate into lineages derived from all three primary germ layers, their use remains ethically controversial. Mesenchymal stromal cells’ (MSCs) utilization is not burdened with such concerns. MSCs were primarily characterized as fibroblastic cells from bone marrow stroma, with the ability to adhere to plastic and form clonogenic colonies (CFU-Fs – colony-forming unit-fibroblasts). Subsequent studies led to their isolation from various other adult or perinatal tissues, including the umbilical cord. Although in most cases MSCs are obtained from umbilical cords’ stroma (Wharton’s jelly), it has been demonstrated that both cord’s lining and endothelial layer of umbilical vein possess the cells that fulfill the minimal criteria for MSCs published in 2006 by the International Society for Cellular Therapy. Since the initial discovery, a number of pre-clinical and clinical studies were conducted with the use of MSCs derived from umbilical cords, targeting diseases such as cancer or autoimmune diseases. Moreover, their secretome may be even more beneficial, providing an opportunity to create cell-free therapies.Running title: The history of human umbilical cord stem cells


2020 ◽  
Vol 65 ◽  
pp. 101351 ◽  
Author(s):  
Shumukh M. Alatyyat ◽  
Houton M. Alasmari ◽  
Omamah A. Aleid ◽  
Mohamed S. Abdel-maksoud ◽  
Nehal Elsherbiny

Sign in / Sign up

Export Citation Format

Share Document